iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
 
 
UK/NICE - Hepatitis C (chronic)-daclatasvir [ID766]
 
 
  Download the PDF here
 
NICE in development [GID-TAG487] Anticipated publication date: August 2015
http://www.nice.org.uk/guidance/indevelopment/gid-tag487/documents
 
Clinical Pharm of HIV & Hepatitis- Population Viral Kinetic Modeling: SVR Prediction in HCV GT-3 Cirrhotic Patients With 24 Weeks of Daclatasvir + Sofosbuvir Administration - (05/29/15)
 
APASL: All-Oral 12-Week Combination Treatment With Daclatasvir and Sofosbuvir in Patients Infected With HCV Genotype 3: ALLY-3 Phase 3 Study - (03/18/15)
 
EASL: DACLATASVIR PLUS SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HCV GENOTYPE 3 INFECTION: INTERIM ANALYSIS OF A FRENCH MULTICENTER COMPASSIONATE USE PROGRAM - (04/24/15)
 
NICE Daclatasvir Evaluation
 
"However, data are available from the AI0444-040 study, which tested the licensed regimen DCV+SOF+/-RBV over 24 weeks. In this study an SVR of 100% was observed in five treatment naive F3-F4 genotype 3 patients (note that only one received DCV+SOF+RBV, the others received DCV+SOF)."

 
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org